Gordian Group hosted a private investor webinar centered around ALS therapies and the merits of investing in orphan drug development.
Date: Thursday, February 20, 2020; 4 – 5 pm ET
Click here to view a recording of the webinar.
Click here to view the speaker bios for the webinar.
Aclipse seeking to raise $6mm of Series A preferred to fund clinical studies. Parties interested in learning more should reach out to Gordian and/or execute the NDA and return; please contact Ajay Bali at 212-486-3600 or firstname.lastname@example.org for info.
This offering is not registered with the SEC, and is being shown to very high net worth potential investors. The offering is not intended for conventional retail participants.
The presenters of this webinar are executives from Aclipse Therapeutics, (www.aclipsetherapeutics.com) an innovative biopharmaceutical company that focuses on developing novel and highly differentiated drugs to address diseases with high unmet medical needs. Aclipse is led by a veteran biopharmaceutical team with three prior drug development success stories together and includes top key opinion leaders, including the second most published researcher on ALS.
The Company’s lead candidate product (M102) represents a novel approach for treating Amyotrophic Lateral Sclerosis, more commonly known as ALS or Lou Gehrig’s disease. M102 is eligible for FDA Fast Track, Breakthrough Therapy, and Priority Review. These designations reduce costs, accelerate the timeline to bring products to market and provide market protection thereby mitigating risks associated with early-stage drug development.